Mass Spectrometric Analysis of Neurologically-Relevant Molecules

Total Page:16

File Type:pdf, Size:1020Kb

Mass Spectrometric Analysis of Neurologically-Relevant Molecules Mass Spectrometric Analysis of Neurologically-Relevant Molecules Item Type text; Electronic Dissertation Authors Smith, Catherine L. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 03/10/2021 20:43:26 Link to Item http://hdl.handle.net/10150/626689 MASS SPECTROMETRIC ANALYSIS OF NEUROLOGICALLY-RELEVANT MOLECULES by Catherine L. Smith ______________________________________________ Copyright © Catherine L. Smith 2018 A Dissertation Submitted to the Faculty of the DEPARTMENT OF CHEMISTRY AND BIOCHEMISTRY In Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY WITH A MAJOR IN CHEMISTRY In the Graduate College THE UNIVERSITY OF ARIZONA 2018 2 STATEMENT BY AUTHOR This dissertation has been submitted in partial fulfillment of the requirements for an advanced degree at the University of Arizona and is deposited in the University Library to be made available to borrowers under rules of the Library. Brief quotations from this dissertation are allowable without special permission, provided that an accurate acknowledgement of the source is made. Requests for permission for extended quotation from or reproduction of this manuscript in whole or in part may be granted by the head of the major department or the Dean of the Graduate College when in his or her judgment the proposed use of the material is in the interests of scholarship. In all other instances, however, permission must be obtained from the author. SIGNED: Catherine L. Smith 3 DEDICATION For Brandon I couldn’t have done this without you. 4 TABLE OF CONTENTS TITLE PAGE LIST OF FIGURES 13 LIST OF TABLES 17 LIST OF ABBREVIATIONS 18 LIST OF CONTRIBUTORS 21 ABSTRACT 22 CHAPTER 1. Introduction: Quantifying neurochemicals with mass 23 spectrometry 1.1 Introduction 23 1.2 Sampling and analysis of neurochemicals 25 1.2.1 Ex situ 26 1.2.1.1 Affinity assays 26 1.2.1.2 Separation and detection techniques 27 1.2.2 In vitro 30 1.2.2.1 Biological fluids 30 1.2.2.2 Cell models 31 1.2.3 In vivo 31 1.2.3.1 Direct measurement techniques 32 1.2.3.2 Microdialysis 32 1.3 Tandem mass spectrometry 36 1.4 Neurotransmission in insects 42 1.4.1 Classical neurotransmission 43 1.4.2 Quantitation of neurotransmitters 46 5 1.5 Drug penetration of the blood-brain barrier 47 1.5.1 Mechanisms of BBB penetration 48 1.5.2 Peptide-based drug development 50 1.5.3 Current measurement techniques and challenges 51 1.6 Overview 53 CHAPTER 2. Separation-free quantitation of biogenic amines in 55 brain tissue with mass spectrometry 2.1 Introduction 56 2.2 Materials and methods 59 2.2.1 Chemicals and reagents 59 2.2.2 Rats 59 2.2.3 Unilateral 6-hydroxydopamine (6-OHDA) lesion 59 method 2.2.4 Amphetamine-induced rotation 60 2.2.5 Rat tissue collection and preparation 60 2.2.6 Drosophila melanogaster 60 2.2.7 Apis mellifera 61 2.2.8 Derivatization reaction 62 2.2.9 Mass spectrometric detection and quantitation 63 2.3 Results and Discussion 63 2.3.1 Mass spectrometric detection of labeled biogenic 63 amines 2.3.2 Comparison to “gold standard” LC-EC 75 2.3.3 Quantification of biogenic amines in insect brain 80 homogenate 6 2.3.4 Sexual dimorphism was not detected across three 85 Drosophila strains 2.3.5 Deletion of ABC transporter does not affect 87 whole-head histamine 2.3.6 Genetic inactivation of DAT in Drosophila 89 melanogaster does not systematically alter whole- head biogenic amine content 2.4 Conclusions 90 2.5 Author contributions 90 2.6 Acknowledgments 91 CHAPTER 3. Nosema ceranae parasitism in honey bees (Apis 92 mellifera) increases biogenic amines associated with foraging behavior and alters olfactory learning and memory 3.1 Introduction 93 3.2 Materials and Methods 95 3.2.1 Animals 95 3.2.2 Feeding 95 3.2.3 Nosema inoculum 96 3.2.4 Spore counts 97 3.2.5 Learning and memory 97 3.2.6 Amino acid analysis of brain tissue and pollen 98 3.2.7 Biogenic amine analysis of brain tissue 101 3.2.8 Statistics 102 3.3 Results and Discussion 102 7 3.3.1 Odor-associative learning and memory in nurse- 102 and forager-aged bees 3.3.2 Amino acid concentrations in the whole brain of 106 nurse- and forager-aged bees 3.3.3 Biogenic amine levels in the whole brain of nurse- 112 and forager-aged bees 3.3.4 Comparing whole-brain content of compounds 118 along biological synthesis pathways can elucidate mechanisms of change in infected bees 3.4 Conclusions 122 3.5 Author Contributions 123 3.6 Acknowledgments 124 CHAPTER 4. Glycosylation of peptide-based drug candidates 125 improves in vivo stability and penetration of the blood-brain barrier 4.1 Introduction 126 4.2 Materials and Methods 131 4.2.1 Chemicals and reagents 131 4.2.2 Peptide synthesis 131 4.2.3 MS identification and quantification of peptides 131 4.2.4 In vitro stability of peptides 133 4.2.5 Animals 133 4.2.6 Carotid artery catheterization 133 4.2.7 Microdialysis surgery 134 4.2.8 Microdialysis and blood draws 135 8 4.3 Results and Discussion 135 4.3.1 High ion throughput of glycosylated peptides 135 during tandem MS yields lower limits of detection 4.3.2 Glycosylated compounds have improved in vitro 144 stability 4.3.3 “Shotgun microdialysis” for direct comparison of 149 in vivo lifetime and BBB penetration of peptide derivatives 4.4 Conclusions 152 4.5 Author Contributions 154 4.6 Acknowledgements 155 CHAPTER 5. Identification of optimal structural modifications for 156 the improvement of peptide-based drug delivery properties: an Angiotensin 1-7 study of in vivo stability and BBB penetration 5.1 Introduction 157 5.2 Materials and Methods 161 5.2.1 Chemicals and reagents 161 5.2.2 Animals 161 5.2.3 Peptide synthesis 162 5.2.4 Mass spectrometric identification and 162 quantification of compounds 5.2.5 In vitro stability of Angiotensin derivatives. 162 5.2.6 Carotid artery catheterization 164 5.2.7 Microdialysis surgery 165 9 5.2.8 Microdialysis and blood draws 165 5.3 Results and Discussion 166 5.3.1 Mass spectrometric identification and 166 quantification of compounds 5.3.2 Modified compounds have increased in vitro 175 lifetime 5.3.3 Non-selective protein binding may decrease free 179 fraction of peptides 5.3.4 “Shotgun microdialysis” allows for the direct 181 comparison of in vivo lifetime and BBB penetration of Ang 1-7 derivatives 5.4 Conclusions 192 5.5 Author Contributions 193 5.6 Acknowledgments 193 CHAPTER 6. Conclusions and future directions 194 6.1 Expanding the portfolio of BzCl-DI-MS 195 6.1.1 Increasing the number of amine compounds 195 being investigated 6.1.2 Application to additional factors in honey bee hive 196 health 6.2 Glycosylation and other modifications for improved 200 pharmaceutical properties of peptide-based drugs 6.2.1 Investigation of apparent PACAP degradation 202 10 6.2.2 Positive and negative controls for blood-brain 205 barrier penetration will strengthen our methodology 6.3 Potential routes for the elucidation of enkephalin 207 dynamics in vivo 6.3.1 Quantitation of enkephalins in chronic pain 209 models 6.3.2 Pharmaceutical probing of enkephalin dynamics 209 6.4 Concluding remarks 211 APPENDIX A Procedure: Benzoyl Chloride Labeling Reaction 214 APPENDIX B Quantification of endogenous opioid peptide 216 dynamics in the anterior cingulate cortex by online- preservation microdialysis B.1 Introduction 217 B.2 Materials and Methods 219 B.2.1 Chemicals 219 B.2.2 Statistical analysis & validation criteria 219 B.2.3 Animals 220 B.2.4 Intracranial (ACC) cannula implantation for 221 microdialysis B.2.5 CSF collection from cisterna magna for in vitro 221 experiments B.2.6 In vivo microdialysis procedure 222 B.2.7 Online-preservation system 223 3 B.2.8 Sample preparation for nano LC-MS analysis 224 11 B.2.9 Nano LC-MS3 analysis of opioids 224 B.2.10 Flow-injection MS study of opioid degradation 225 B.3 Results and Discussion 226 B.3.1 Chip-based ESI for improved nano LC-MS3 226 quantification of endogenous opioids B.3.2 Initial in vivo measurements in the ACC and 231 degradation of opioid peptides B.3.3 Online-preservation of endogenous peptides 237 B.3.4 Online-preservation microdialysis allowed 239 quantifiable measurement of EOPs in the ACC B.3.5 Identification and quantification of methionine 239 enkephalin sulphoxide B.3.6 Endomorphin II is present in dialysate from the 241 ACC B.3.7 Stimulated release of enkephalins in the ACC 241 B.4 Conclusions 244 B.5 Author Contributions 246 B.6 Acknowledgements 246 APPENDIX C Compound structures, mass spectra, and 247 chromatograms REFERENCES 261 12 LIST OF FIGURES FIGURE TITLE PAGE 1.1 Principles of microdialysis 34 1.2 Principles of electrospray ionization 38 1.3 Neural transmission 45 1.4 Mechanisms of penetration of the blood-brain barrier 49 2.1 Schotten-Baumann reaction mechanism 64 2.2 Benzoyl chloride derivitization 65 2.3 Workflow for sample preparation 67 2.4 MS2 spectra for target compounds 68 2.5 Representative calibration curves 69 2.6 Labeled compounds show stability against oxidation 74 2.7 Comparison to existing LC-EC method for validation of 77 quantitation 2.8 Dopamine and serotonin correlations between methods 79 2.9 Biogenic amine quantification in honey bees matches previously 81 reported results 2.10 Biogenic amine content (ng/head) in Drosophila melanogaster 86 whole heads, by sex 2.11 Biogenic amine content (ng/head) in Drosophila melanogaster 88 whole heads, by strain 3.1 Honey bee learning and memory trials 104 3.2 N.
Recommended publications
  • Behavioral and Brain Sciences Plasticity: Implications for Opioid
    Behavioral and Brain Sciences http://journals.cambridge.org/BBS Additional services for Behavioral and Brain Sciences: Email alerts: Click here Subscriptions: Click here Commercial reprints: Click here Terms of use : Click here Plasticity: Implications for opioid and other pharmacological interventions in specific pain states Anthony H. Dickenson Behavioral and Brain Sciences / Volume 20 / Issue 03 / September 1997, pp 392 ­ 403 DOI: null, Published online: 08 September 2000 Link to this article: http://journals.cambridge.org/abstract_S0140525X97241488 How to cite this article: Anthony H. Dickenson (1997). Plasticity: Implications for opioid and other pharmacological interventions in specific pain states. Behavioral and Brain Sciences,20, pp 392­403 Request Permissions : Click here Downloaded from http://journals.cambridge.org/BBS, IP address: 144.82.107.43 on 10 Aug 2012 BEHAVIORAL AND BRAIN SCIENCES (1997) 20, 392±403 Printed in the United States of America Plasticity: Implications for opioid and other pharmacological interventions in specific pain states Anthony H. Dickenson Department of Pharmacology, University College London, London WC1E 6BT, United Kingdom Electronic mail: anthony.dickenson6ucl.ac.uk Abstract: The spinal mechanisms of action of opioids under normal conditions are reasonably well understood. The spinal effects of opioids can be enhanced or reduced depending on pathology and activity in other segmental and nonsegmental pathways. This plasticity will be considered in relation to the control of different pain states using opioids. The complex and contradictory findings on the supraspinal actions of opioids are explicable in terms of heterogeneous descending pathways to different spinal targets using multiple transmitters and receptors ± therefore opioids can both increase and decrease activity in descending pathways.
    [Show full text]
  • Cardioprotective Properties of Opioid Receptor Agonists in Rats with Stress-Induced
    Cardioprotective Properties of Opioid Receptor Agonists in Rats with Stress-Induced Cardiac Injury Ekaterina S. Prokudinaa B, Leonid N. Maslova* A, D, E, F, Natlia V. Naryzhnayaa B,G, Sergey Yu. Tsibulnikova B,C,E, Yury B. Lishmanova,b D, John E. Madias PhD c D,E, Peter R. Oeltgen PhD d D,E aLaboratory of Experimental Cardiology, Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences 634012 Tomsk, Russia. bLaboratory of Nuclear Medicine, National Research Tomsk Polytechnic University, Tomsk, Russia. cIcahn School of Medicine at Mount Sinai, and the Division of Cardiology, Elmhurst Hospital Center, New York, New York, USA. dDepartment of Pathology, University of Kentucky College of Medicine, Lexington, KY, USA * Correspondence: Leonid N. Maslov, MD, PhD, DSci, Professor of Pathological Physiology Laboratory of Experimental Cardiology, Federal State Budgetary Scientific Institution «Research Institute for Cardiology», Kyevskaya 111A, 634012 Tomsk, Russia Tel. +7 3822 262174 E-mail address: [email protected] Short title: Stress cardiomyopathy and opioid receptors Summary Purpose The objectives of this study were to investigate the role of endogenous opioids in the mediation of stress-induced cardiomyopathy (SIC), and to evaluate which opioid receptors regulate heart resistance to immobilization stress. Methods Wistar rats were subjected to 24 h 1 immobilization stress. Stress-induced heart injury was assessed by 99mTc-pyrophosphate accumulation in the heart. The opioid receptor (OR) antagonists (naltrexone, NxMB - naltrexone methyl bromide, MR 2266, ICI 174.864) and agonists (DALDA, DAMGO, DSLET, U-50,488) were administered intraperitoneally prior to immobilization and 12 h after the start of stress. In addition, the selective µ OR agonists PL017 and DAMGO were administered intracerebroventricularly prior to stress.
    [Show full text]
  • Morphine Indiscriminatingly Overstimulates All Opioid Receptors Including Those Not Involved in (Morphine) Pain Control (Exogenous)
    Extensions des propriétés des inhibiteurs mixtes des enképhalinases aux douleurs de la sphère cranio-faciale. Nouvelles applications à la migraine et aux douleurs de la cornée. Bernard P. Roques Professeur Emérite, Université Paris Descartes Unité 1267 Inserm, 4 avenue de l’Observatoire, 75006 Paris. ATHS Biarritz, 1-4 Octobre 2019 CONFIDENTIAL 1 Endorphins and their receptors. Endomorphin-1 Tyr – Pro – Trp – Phe – NH2 Endomorphin-2 Tyr – Pro – Phe – Phe – NH2 2 2 Drug Discovery : designing the ideal opioid (From B.L. Kieffer, Nature (2016), 537, 170-171) 3 Three levels of pain control by endogenous opioid system (EOS) EOS EOS Attacking pain at EOS its source Relieving or reducing pain at its source More than 50% of MO effects are attributable to peripheral neurons (nociceptors) Roques, B.P., Fournié-Zaluski, M.C. and Wurm, M., Nature Reviews Drug Discovery, 2012 4 DENKIs: mechanism of action The endogenous opioid system (EOS) is present at all levels of physiological-nociceptive control i.e. periphery, spinal cord and brain Elements of the EOS are opioid receptors, enkephalins and their inactivating enzymes Dual Inhibitors of ENKephalinases (DENKIs) potentiate physiological functions of DENKI enkephalins (e.g. pain control) only on those pathways where they are tonically released Enkephalinases APN NEP No adverse effects Enkephalins Y G G F M(L) (endogenous) Opioid receptors Morphine indiscriminatingly overstimulates all opioid receptors including those not involved in (Morphine) pain control (exogenous) Adverse effects 5 Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets in a murine model of bone cancer-induced pain.
    [Show full text]
  • The Inhibition of Enkephalin Catabolism by Dual Enkephalinase Inhibitor: a Novel Possible Therapeutic Approach for Opioid Use Disorders
    Alvarez-Perez Beltran (Orcid ID: 0000-0001-8033-3136) Maldonado Rafael (Orcid ID: 0000-0002-4359-8773) THE INHIBITION OF ENKEPHALIN CATABOLISM BY DUAL ENKEPHALINASE INHIBITOR: A NOVEL POSSIBLE THERAPEUTIC APPROACH FOR OPIOID USE DISORDERS ALVAREZ-PEREZ Beltran1*, PORAS Hervé 2*, MALDONADO Rafael1 1 Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona Biomedical Research Park, c/Dr Aiguader 88, 08003 Barcelona, Spain, 2 Pharmaleads, Paris BioPark, 11 Rue Watt, 75013 Paris, France *Both authors participated equally to the manuscript Correspondence: Rafael Maldonado, Laboratori de Neurofarmacologia, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona (PRBB), c/Dr. Aiguader, 88, 08003 Barcelona, Spain. E-mail: [email protected] ABSTRACT Despite the increasing impact of opioid use disorders on society, there is a disturbing lack of effective medications for their clinical management. An interesting innovative strategy to treat these disorders consists in the protection of endogenous opioid peptides to activate opioid receptors, avoiding the classical opioid-like side effects. Dual Enkephalinase Inhibitors (DENKIs) physiologically activate the endogenous opioid system by inhibiting the enzymes responsible for the breakdown of enkephalins, protecting endogenous enkephalins, increasing their half-lives and physiological actions. The activation of opioid receptors by the increased enkephalin levels, and their well-demonstrated safety, suggest that DENKIs could represent a novel analgesic therapy and a possible effective treatment for acute opioid withdrawal, as well as a promising alternative to opioid substitution therapy minimizing side effects. This new pharmacological class of compounds could bring effective and safe medications avoiding the This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record.
    [Show full text]
  • (D-Ala*)Deltorphin II: D,-Dependent Stereotypies and Stimulation of Dopamine Release in the Nucleus Accumbens
    The Journal of Neuroscience, June 1991, 17(6): 1565-l 576 (D-Ala*)Deltorphin II: D,-dependent Stereotypies and Stimulation of Dopamine Release in the Nucleus Accumbens R. Longoni,’ L. Spina,’ A. Mulas,’ E. Carboni,’ L. Garau,’ P. Melchiorri,2 and G. Di Chiaral ‘Institute of Experimental Pharmacology and Toxicology, University of Cagliari, 09100 Cagliari, Italy and 21nstitute of Medical Pharmacology, University of Rome “La Sapienza,” 00185 Rome, Italy In order to investigate the relative role of central 6- and has been implicated in the stimulant actions of systemic opiates. F-opioid receptors in behavior, the effects of (D- Morphine-like opiates stimulate DA release preferentially in the Ala*)cleltorphin II, a natural Gopioid peptide, and PL017, nucleus accumbens (Di Chiara and Imperato, 1988a) and elicit a beta-casomorphin derivative specific for mu receptors, hypermotility sensitive to blockade by the DA D, receptor an- were compared after local intracerebral and intraventricular tagonist SCH 23390 (Longoni et al., 1987a). Intra-accumbens administration. lntracerebral infusion of the two peptides was infusion of opioid peptides elicits motor stimulation, but this done bilaterally in the limbic nucleus accumbens and in the action seems independent from DA, being resistant to classic ventral and dorsal caudate putamen of freely moving rats DA-receptor antagonists (neuroleptics; Pert and Sivit, 1977; Ka- through chronic intracerebral cannulas. After intra-accum- livas et al., 1983). Moreover, the syndrome elicited by intra- bens infusion, the two peptides elicited marked but opposite accumbens opiates is biphasic, as motor stimulation is typically behavioral effects: while (o-Ala2)deltorphin II evoked dose- preceded by motor inhibition and catalepsy (Costa11et al., 1978).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.247,609 B2 Roques Et Al
    USOO82476.09B2 (12) United States Patent (10) Patent No.: US 8.247,609 B2 Roques et al. (45) Date of Patent: Aug. 21, 2012 (54) AMINOACID DERIVATIVES CONTAININGA FOREIGN PATENT DOCUMENTS DSULFANYL GROUPIN THE FORM OF EP O262O53 3, 1988 MIXED DISULEANYLAND AMINOPEPTIDASEN INHIBITORS (Continued) (75) Inventors: Bernard Roques, Paris (FR): Marie-Claude Fournie-Zalluski, Paris OTHER PUBLICATIONS (FR) Silverman (The Organic Chemistry of Drug Design and Drug Action, (73) Assignee: Pharamleads, Paris (FR) 1992, Academic Press Inc.).* (*) Notice: Subject to any disclaimer, the term of this (Continued) patent is extended or adjusted under 35 U.S.C. 154(b) by 868 days. (21) Appl. No.: 12/146,941 Primary Examiner — Susanna Moore Assistant Examiner — Jennifer C Sawyer (22) Filed: Jun. 26, 2008 (74) Attorney, Agent, or Firm — Harness, Dickey & Pierce, (65) Prior Publication Data P.L.C. US 2009/OO12153 A1 Jan. 8, 2009 Related U.S. Application Data (57) ABSTRACT (63) Continuation-in-part of application No. 12/084,091, The invention relates to novel compounds of formula (I): filed as application No. PCT/EP2006/067711 on Oct. HN CH(R)-CH S S CH-CH(R) CONH 24, 2006. Rs, wherein R is a hydrocarbon chain, phenyl or benzyl (30) Foreign Application Priority Data radical, methylene radical substituted by a 5 or 6 atom het erocycle; R is a phenyl or benzyl radical, a 5 or 6 atom Oct. 25, 2005 (FR) ...................................... O5 10862 aromatic heterocycle, methylene group Substituted by a 5 or 6 May 5, 2006 (FR) ...................................... O6 O4030 atom heterocycle; Rs is a CH(R)—COOR radical, wherein R is hydrogen, an OH or OR group, a saturated hydrocarbon (51) Int.
    [Show full text]
  • Rôles Des Récepteurs Nucléaires Nur77 Et Nor-1 Et Des
    Rôles des récepteurs nucléaires Nur77 et Nor-1 et des neuropeptides enképhaline et dynorphine dans les comportements médiés par la dopamine et induits par les psychostimulants Thèse Céline Hodler Programme de doctorat en Neurobiologie Philosophiae doctor (Ph.D.) Faculté de médecine Québec, Canada © Céline Hodler, 2012 RÉSUMÉ Cette thèse démontre que les récepteurs nucléaires Nur77 et Nor-1 ainsi que les neuropeptides dynorphine (DYN) et enképhaline (ENK) sont des facteurs déterminants de la régulation du système dopaminergique. Notre premier manuscrit démontre d’une part que Nur77 et Nor-1 sont très clairement impliqués dans la régulation de l’homéostasie du système dopaminergique et qu’ils y jouent des rôles distincts, voire opposés, dans les conditions basales et dans les réponses comportementales et biochimiques aux psychostimulants. La délétion génétique de Nur77 augmente la proportion des récepteurs D2 en haute affinité (D2high), supprime les stéréotypies et perturbe la persistance de la préférence de place induites par l’administration répétée de psychostimulants. À l’inverse, la délétion de Nor-1 diminue la proportion des récepteurs D2high, atténue les comportements moteurs en réponse à l’amphétamine et supprime la sensibilisation comportementale. La délétion de Nor-1 module également l’expression de la DYN et de l’ENK favorisant ainsi une diminution de la réponse comportementale alors que celle de Nur77 induit l’effet inverse. Ainsi, Nor-1 et Nur77 jouent des rôles opposés, la délétion de Nor-1 tempère les comportements moteurs, celle de Nur77 les exacerbe. Notre second manuscrit démontre d’autre part que la DYN et l’ENK sont toutes deux nécessaires et ont des rôles opposés dans la manifestation des comportements de base médiés par la dopamine.
    [Show full text]
  • Replacement of Current Opioid Drugs Focusing on MOR-Related Strategies
    JPT-107519; No of Pages 17 Pharmacology & Therapeutics xxx (2020) xxx Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Replacement of current opioid drugs focusing on MOR-related strategies Jérôme Busserolles a,b, Stéphane Lolignier a,b, Nicolas Kerckhove a,b,c, Célian Bertin a,b,c, Nicolas Authier a,b,c, Alain Eschalier a,b,⁎ a Université Clermont Auvergne, INSERM, CHU, NEURO-DOL Pharmacologie Fondamentale et Clinique de la douleur, F-63000 Clermont-Ferrand, France b Institut ANALGESIA, Faculté de Médecine, F-63000 Clermont-Ferrand, France c Observatoire Français des Médicaments Antalgiques (OFMA), French monitoring centre for analgesic drugs, CHU, F-63000 Clermont-Ferrand, France article info abstract Available online xxxx The scarcity and limited risk/benefit ratio of painkillers available on the market, in addition to the opioid crisis, warrant reflection on new innovation strategies. The pharmacopoeia of analgesics is based on products that are often old and derived from clinical empiricism, with limited efficacy or spectrum of action, or resulting in Keywords: an unsatisfactory tolerability profile. Although they are reference analgesics for nociceptive pain, opioids are sub- Analgesia ject to the same criticism. The use of opium as an analgesic is historical. Morphine was synthesized at the begin- Mu opioid receptors (MORs) ning of the 19th century. The efficacy of opioids is limited in certain painful contexts and these drugs can induce Opioid adverse side effects potentially serious and fatal adverse effects. The current North American opioid crisis, with an ever-rising number Opioid abuse and misuse of deaths by opioid overdose, is a tragic illustration of this.
    [Show full text]
  • Inhibiting the Breakdown of Endogenous Opioids and Cannabinoids to Alleviate Pain
    REVIEWS Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain Bernard P. Roques1,2, Marie-Claude Fournié-Zaluski1 and Michel Wurm1 Abstract | Chronic pain remains unsatisfactorily treated, and few novel painkillers have reached the market in the past century. Increasing the levels of the main endogenous opioid peptides — enkephalins — by inhibiting their two inactivating ectopeptidases, neprilysin and aminopeptidase N, has analgesic effects in various models of inflammatory and neuropathic pain. Stemming from the same pharmacological concept, fatty acid amide hydrolase (FAAH) inhibitors have also been found to have analgesic effects in pain models by preventing the breakdown of endogenous cannabinoids. Dual enkephalinase inhibitors and FAAH inhibitors are now in early-stage clinical trials. In this Review, we compare the effects of these two potential classes of novel analgesics and describe the progress in their rational design. We also consider the challenges in their clinical development and opportunities for combination therapies. Pain is a unique, conscious experience with sensory- to the market. There is an urgent need for novel treat- Fibromyalgia A disorder of unknown discriminative, cognitive-evaluative and affective- ments for all types of pain, particularly neuropathic pain, 1 aetiology that is characterized emotional components . Transient and acute pain can be that show greater efficacy, better tolerability and wider by widespread pain, abnormal effectively alleviated by activating the endogenous safety margins11. pain processing, sleep opioid system, which has a key role in discriminating One innovative approach12 for the development disturbance, fatigue and between innocuous and noxious sensations2,3. However, of analgesics is based on the fact that the painkillers often psychological distress.
    [Show full text]
  • Opioid Peptides: Medicinal Chemistry, 69
    Opioid Peptides: Medicinal Chemistry DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration Opioid Peptides: Medicinal Chemistry Editors: Rao S. Rapaka, Ph.D. Gene Barnett, Ph.D. Richard L. Hawks, Ph.D. Division of Preclinical Research National Institute on Drug Abuse NIDA Research Monograph 69 1986 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY COHEN, M.D. Temple University School of Medicine Los Angeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic lnstitute National Federation of Parents for Troy, New York Drug Free Youth RICHARD E. BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTEMAN Langley Porter Neuropsychiatric lnstitute San Francisco, California Alcohol and Drug Problems Association of North America WashIngton, DC DENISE KANDEL, Ph.D. GILBERT J. BOTVIN, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
    [Show full text]
  • List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify
    List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify, abnormal basal ganglia function, abuse of medicines, Aceperone, Acepromazine, Aceprometazine, Acetildenafil, Aceto phenazine, Acetoxy Dipt, Acetyl morphone, Acetyl propionyl morphine, Acetyl psilocin, Activation syndrome, acute anxiety, acute hypertension, acute panic attacks, Adderall, Addictions to drugs, Addictions to medicines, Addictions to substances, Adrenorphin, Adverse effects of psychoactive drugs, adverse reactions to medicines, aggression, aggressive, aggressiveness, agitated depression, Agitation and restlessness, Aildenafil, Akuammine, alcohol abuse, alcohol addiction, alcohol withdrawl, alcohol-related brain damage, alcohol- related liver damage, alcohol mix with medicines for adverse reaction, Alcoholism, Alfetamine, Alimemazine, Alizapride, Alkyl nitrites, allergic breathing reactions to meds, choking to anaphallectic shock, & death; allergic skin reactions to meds, rash, itchyness, hives, welts, etc, Alletorphine, Almorexant, Alnespirone, Alpha Ethyltryptamine, Alpha Neoendorphin, alterations in brain hormones, alterations in mental status, altered consciousness, altered mind, Altoqualine, Alvimopan, Ambien, Amidephrine, Amidorphin, Amiflamine, Amisulpride, Amphetamines, Amyl nitrite, Anafranil, Analeptic, Anastrozole, Anazocine, Anilopam, Antabuse, anti anxiety meds, anti dopaminergic activity, anti seizure meds, Anti convulsants, Anti depressants, Anti emetics, Anti histamines, anti manic meds, anti parkinsonics, Anti psychotics, Anxiety disorders,
    [Show full text]
  • Low Doses of Cyclic AMP-Phosphodiesterase Inhibitors
    B R A I N R E S E A R C H 1 2 3 1 ( 2 0 0 8 ) 1 6 – 2 4 ava i l a b l e a t w w w. s c i e n c e d i re c t . c o m w w w. e l s ev i e r. c o m / l o c a t e / b ra i n re s Research Report Low doses of cyclic AMP-phosphodiesterase inhibitors rapidly evoke opioid receptor-mediated thermal hyperalgesia in naïve mice which is converted to prominent analgesia by cotreatment with ultra-low-dose naltrexone Stanley M. Crain⁎, Ke-Fei Shen Department of Neuroscience, Albert Einstein College of Medicine, Yeshiva University, 1300 Morris Park Avenue, Bronx, NY 10461, USA A R T I C L E I N F O A B S T R A C T Article history: Systemic (s.c.) injection in naïve mice of cyclic AMP-phosphodiesterase (cAMP-PDE) Accepted 3 July 2008 inhibitors, e.g. 3-isobutyl-1-methylxanthine [(IBMX) or caffeine, 10 mg/kg] or the more Available online 12 July 2008 specific cAMP-PDE inhibitor, rolipram (1 μg/kg), rapidly evokes thermal hyperalgesia (lasting >5 h). These effects appear to be mediated by enhanced excitatory opioid receptor signaling, Keywords: as occurs during withdrawal in opioid-dependent mice. Cotreatment of these mice with Endogenous opioid hyperalgesia ultra-low-dose naltrexone (NTX, 0.1 ng/kg–1 pg/kg, s.c.) results in prominent opioid analgesia Endogenous opioid analgesia (lasting >4 h) even when the dose of rolipram is reduced to 1 pg/kg.
    [Show full text]